

North Central Cancer Treatment Group

N0626: Phase II Randomized Study Pemetrexed With Sorafenib versus Pemetrexed Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Addendum 9 – November 27, 2009

**Summary**

- The Investigator Brochures (IB), Versions dated May 23, 2009 and June 24, 2009, for Pemetrexed have been received. The consent form risks and drug information section have been updated accordingly.
- Editorial/administrative changes.

**Replacement pages are included. Please incorporate into the protocol and keep this addendum with your protocol.**

**Title page**

Updated to reflect Addendum 9 and revised NCI version date.

**Section 15.0**

**Drug Information**

Page 60:

Due to the receipt of the updated IBs for Pemetrexed, Section 15.23 has been updated as follows:

- ~~Very common~~ **Likely (>20%)**: Neutropenia, anemia, nausea, vomiting, diarrhea, fatigue, anorexia, mild hair loss, abdominal pain, and itchy skin rash, dyspnea, weakness, constipation, fever, dehydration, mouth ulcers, **cough, headache** (*newly added*)
- ~~Common~~ **Less Likely ≤20%**: Thrombocytopenia, short-lived increases in hepatic function tests, elevated creatinine, cellulitis, and urinary tract infection, mucositis, conjunctivitis, injection site reactions, thromboembolism, edema, **infection in the blood with fever, decreased kidney function, inflammation of the skin, blood clots, burning, itchy, red sore eyes, dyspepsia, dysgeusia; angina, heart attack, increased heart rate, peripheral neuropathy, pneumonitis/pneumonia, insomnia, gastrointestinal bleeding, bowel obstruction, nephropathy/acute renal failure, (all newly added) arrhythmia** (*abnormal heart rhythm moved from Uncommon and reworded*)
- ~~Uncommon~~ **Rare but serious (<2-3%)**: Allergic reaction, ~~abnormal heart rhythm~~ (*moved to Less Likely and reworded*) **colitis** (*newly added*)

**Appendix I**

**Consent Form**

Page 9:

Due to the receipt of the updated IBs for Pemetrexed, the risks have been updated as follows:

**Likely risks of Pemetrexed (Alimta) (events that occur greater than 20% of time)**

- Low white blood cells which may lead to infection (**leucopenia**) (*wording expanded*)
- Low red blood cells which may lead to fatigue and/or less energy (**Anemia**) (*wording expanded*)
- Nausea - Feeling sick to the stomach
- Vomiting - Throwing up
- Diarrhea - Loose stools
- Loss of body fluids (dehydration which may require intravenous fluids)

- Loss of appetite (**anorexia**) (*wording expanded*)
- Mild hair loss (Alopecia)
- Itchy skin rash
- Shortness of breath (**Dyspnea**) (*wording expanded*)
- Abdominal (stomach) pain
- Weakness (**Asthenia**) (*wording expanded*)
- Constipation (irregular or difficulty in passing stool)
- Fever (**Pyrexia**) (*wording expanded*)
- Mouth ulcers (similar to canker sores) (**Stomatitis**) (*wording expanded*)
- **Cough** (*newly added*)
- **Headache** (*newly added*)
- **Feeling tired (fatigue)** (*newly added*)

**Less likely risks of Pemetrexed (Alimta)** (*events that occur less than or equal to 20% of time*)

- Fall in the platelet count that may lead to the risk of bruising and bleeding after an injury (**thrombocytopenia**) (*wording expanded*)
- Infection in the blood with fever (caused by a fall in the number of white blood cells)
- Change in liver function tests (tests that show how the liver is working)
- Decrease in kidney function
- Inflammation (swelling, redness, pain) of the skin
- Infection such as urinary tract infection
- Blood clots
- Burning, itchy, red sore eyes with lots of watering
- Increase in body fluids (swelling, edema)
- Sores on the skin or local redness, pain, and/or swelling at the site of the injection
- **Infection of the skin and surrounding tissue (Cellulitis)** (*newly added*)
- **Indigestion or heartburn (Dyspepsia)** (*newly added*)
- **Change in taste sensation (Dysgeusia)** (*newly added*)
- **Chest pain that occurs when your heart doesn't get enough oxygen. It can be a warning sign of a heart attack (Angina – unstable)** (*newly added*)
- **Lack of oxygen to the heart muscle which can cause damage to the heart (Heart attack)** (*newly added*)
- **Increased heart rate** (*newly added*)
- **Numbness, tingling, or inflammation of the nerves (usually in the hands and feet), which may be painful (Peripheral neuropathy)** (*newly added*)
- **Inflammation/infection of the lungs (Pneumonitis/pneumonia)** (*newly added*)
- **Difficulty falling or staying asleep (Insomnia)** (*newly added*)
- **Abnormal heart beat (Arrhythmia)** (*moved from Rare but Serious and reworded*)
- **Bleeding from the stomach, large intestine and/or small intestine (gastrointestinal bleeding)** (*newly added*)
- **Blockage in the intestines (bowel obstruction)** (*newly added*)
- **Infection around the eye, also called pink eye (Conjunctivitis)** (*newly added*)
- **Damage to the kidneys, which may be temporary or permanent (Nephropathy/acute renal failure)** (*newly added*)

**Rare but serious risks of Pemetrexed (Alimta) (events that occur less than 2-3% of time)**

- Allergic reaction
- ~~Abnormal heart rhythm~~ (moved to *Less Likely and reworded*)
- **Inflammation in the colon (Colitis) has been reported in patients taking Pemetrexed** (newly added)

You should not take aspirin or aspirin-like drugs (Advil®, Motrin®, Aleve®, etc.) for two days before getting treatment, on the day of treatment, and for two days after getting treatment with pemetrexed. Aspirin and aspirin-like drugs can cause trouble with your ability of passing pemetrexed through your body, raising the risk of low blood counts that can lead to infections and bleeding. Tylenol, however, may be used.